AI Summary & Key Takeaways
AI InsightThe diagnostic sensitivity, accuracy, and negative predictive value of EBUSTBNA per patient were 78.2%, 91.8%, and 88.3%, respectively.
📌 3 Key Takeaways
Abstract
Background/aim: The aim of this study was to determine the diagnostic performance of endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) in the diagnosis of mediastinal and hilar lymph nodes (LNs) in patients with known extrapulmonary malignancy. Materials and methods: Between March 2011 and August 2013, 378 EBUS-TBNA procedures were performed. Sixty-three (16.6%) of these were performed on known extrapulmonary malignancy patients. Results: There were 28 male and 35 female patients, with median ages of 65 years (min max: 53 87) and 57 years (min max: 39 76), respectively. From the 63 cases, 138 lymph nodes (LNs) were sampled with EBUS-TBNA (median: 2 LNs/patient; min max: 1 4). Results of EBUS-TBNA revealed malignancy in 18 (28.5%) and nonmalignancy in 45 (71.5%). In the nonmalignant group, there were false negatives in 5 (7.9%), anthracosis in 13 (20.6%), reactive adenitis in 16 (25.3%), sarcoidosis in 7 (11.1%), and tuberculosis in 2 (3.1%), and 2 were not evaluated (lost to follow-up) (3.1%). The diagnostic sensitivity, accuracy, and negative predictive value of EBUSTBNA per patient were 78.2%, 91.8%, and 88.3%, respectively.